ArticlePLoS computational biology2026
ERFMTDA: Predicting tsRNA-disease associations using an enhanced rotative factorization machine.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
tRNA-derived small RNAs (tsRNAs) have emerged as a novel class of regulatory molecules implicated in the pathogenesis of numerous human diseases, positioning them as promising biomarkers and therapeutic targets. Existing computational methods provide a cost-effective alternative to experimental method, but they tend to ignore biological attributes and complex feature interactions. To overcome these limitations, we propose ERFMTDA, an enhanced rotative factorization machine framework for predicting potential tsRNA-disease associations. ERFMTDA explicitly models complex interactions among heterogeneous biological features while integrating latent structural representations derived from the global association matrix. In addition, a biologically informed negative sampling strategy based on motif-level sequence similarity is introduced to improve the reliability of negative samples. Extensive experiments demonstrate that ERFMTDA consistently surpasses the other eleven state-of-the-art methods. Two case studies on diabetic retinopathy and hepatocellular carcinoma further corroborate the model's ability to prioritize biologically meaningful tsRNA-disease associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.